TY - JOUR
T1 - Antibody-mediated catalysis
T2 - Induction and therapeutic relevance
AU - Mahendra, Ankit
AU - Sharma, Meenu
AU - Rao, Desirazu N.
AU - Peyron, Ivan
AU - Planchais, Cyril
AU - Dimitrov, Jordan D.
AU - Kaveri, Srini V.
AU - Lacroix-Desmazes, Sébastien
N1 - Funding Information:
This work was supported by Centre National de la Recherche Scientifique , by Institut National de la Santé et de la Recherche Médicale , by Université Pierre et Marie Curie-Paris 6 , and by grants from the Indo-French Center for Promotion of Advanced Research (Reference No: 4103-2 ), from Agence Nationale de la Recherche ( ANR-09-GENO-028 ), and from the Japan Sciences and Technology Agency (Tokyo, Japan). I.P. and M.S. were recipients of fellowships from Ministère de la Recherche et de la Technologie (France) and IFCPAR (India), respectively.
PY - 2013/4
Y1 - 2013/4
N2 - Abzymes are immunoglobulins endowed with enzymatic activities. The catalytic activity of an abzyme resides in the variable domain of the antibody, which is constituted by the close spatial arrangement of amino acid residues involved in catalysis. The origin of abzymes is conferred by the innate diversity of the immunoglobulin gene repertoire. Under deregulated immune conditions, as in autoimmune diseases, the generation of abzymes to self-antigens could be deleterious. Technical advancement in the ability to generate monoclonal antibodies has been exploited in the generation of abzymes with defined specificities and activities. Therapeutic applications of abzymes are being investigated with the generation of monoclonal abzymes against several pathogenesis-associated antigens. Here, we review the different contexts in which abzymes are generated, and we discuss the relevance of monoclonal abzymes for the treatment of human diseases.
AB - Abzymes are immunoglobulins endowed with enzymatic activities. The catalytic activity of an abzyme resides in the variable domain of the antibody, which is constituted by the close spatial arrangement of amino acid residues involved in catalysis. The origin of abzymes is conferred by the innate diversity of the immunoglobulin gene repertoire. Under deregulated immune conditions, as in autoimmune diseases, the generation of abzymes to self-antigens could be deleterious. Technical advancement in the ability to generate monoclonal antibodies has been exploited in the generation of abzymes with defined specificities and activities. Therapeutic applications of abzymes are being investigated with the generation of monoclonal abzymes against several pathogenesis-associated antigens. Here, we review the different contexts in which abzymes are generated, and we discuss the relevance of monoclonal abzymes for the treatment of human diseases.
KW - Abzyme therapy
KW - Abzymes
KW - Autoimmune diseases
KW - Catalytic antibodies
UR - http://www.scopus.com/inward/record.url?scp=84877048778&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877048778&partnerID=8YFLogxK
U2 - 10.1016/j.autrev.2012.10.009
DO - 10.1016/j.autrev.2012.10.009
M3 - Review article
C2 - 23207286
AN - SCOPUS:84877048778
SN - 1568-9972
VL - 12
SP - 648
EP - 652
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
IS - 6
ER -